Immix Biopharma Inc IMMX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2
-
Immix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board
-
Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2
-
California Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2)
-
Immix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201
Trading Information
- Previous Close Price
- $1.34
- Day Range
- $1.26–1.66
- 52-Week Range
- $1.26–7.75
- Bid/Ask
- $1.59 / $1.64
- Market Cap
- $44.74 Mil
- Volume/Avg
- 471,998 / 139,636
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 17
- Website
- https://www.immixbio.com
Comparables
Valuation
|
Metric
|
IMMX
|
TCRX
|
ARTV
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.87 | 1.14 | — |
Price/Sales | — | 45.08 | 4.39 |
Price/Cash Flow | — | — | — |
Price/Earnings
IMMX
TCRX
ARTV
Financial Strength
|
Metric
|
IMMX
|
TCRX
|
ARTV
|
|---|---|---|---|
Quick Ratio | 6.65 | 7.72 | 4.43 |
Current Ratio | 7.00 | 7.77 | 4.59 |
Interest Coverage | — | −29.80 | — |
Quick Ratio
IMMX
TCRX
ARTV
Profitability
|
Metric
|
IMMX
|
TCRX
|
ARTV
|
|---|---|---|---|
Return on Assets (Normalized) | −68.40% | −32.50% | −16.21% |
Return on Equity (Normalized) | −81.88% | −54.73% | — |
Return on Invested Capital (Normalized) | −84.48% | −39.01% | — |
Return on Assets
IMMX
TCRX
ARTV
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Mzwcdvrl | Cyrv | $512.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Gpjfywcxn | Kgdtyx | $117.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Mmbvfhsqs | Lwvxp | $111.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Sjhycxmrn | Kbfhpj | $34.4 Bil | |||
| argenx SE ADR
ARGX
| Jftykqzmy | Mthnl | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Dgdwqvk | Rfmbq | $29.2 Bil | |||
| Moderna Inc
MRNA
| Sfpnyyfv | Grcv | $23.1 Bil | |||
| United Therapeutics Corp
UTHR
| Swwdnhr | Mkcyp | $15.8 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Lmdmpjhj | Xxgtm | $13.2 Bil | |||
| Incyte Corp
INCY
| Bhzmjzwq | Sxsxrp | $13.0 Bil |
United States